嵟嬤偺嬈愌

尋媶嬈愌

亂尨挊亃

<堛妛宯尋媶>

1丂Hayashi Y, Liu J-h, Moriguchi H, Takenawa H, Tazawa J, Nakayama E, Marumo F, Sato C: Prevalence of polypoid lesions of the gallbladder in urban and rural areas of Japan: comparison between 1988 and 1993. J Clin Gastroenterol 23:158-159,1996.
2丂Itakura J, Nagayama K, Enomoto N, Sakamoto N, Tazawa J, Izumi N, Marumo F, Sato C: CD81 Nucleotide Mutation in Hepatocellular Carcinoma and No CD81 Polymorphism in Patients with Various Stages of Hepatitis C Virus Infection. J Med Virol 2001,63:22-28.
3丂Nagayama K, Enomoto N, Izumi N, Kurosaki M, Miyasaka Y, Watanabe H, Itakura J, Chen C-H, Tazawa J, Hoshino Y, Ikeda T, Marumo F, Sato C: Sequences in the NS5A protein of hepatitis C virus and the serum ALT response to interferon therapy in Japanese patients. Gut 2001,48:830-835.
4丂Nagayama K, Enomoto N, Miyasaka Y, Kurosaki M, Chen C-H, Sakamoto N, Nakagawa M, Chen C-H, Sato C, Tazawa J, Ikeda T, Izumi N, Watanabe M: Overexpression of interferon-inducible protein 10 in the liver of patients with type I autoimmune hepatitis identified by seppression subtractive hybridization. Am J Gastroenterol 2001,96:2211-2217.
5丂Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, Watanabe M: Number and Position of Mutations in the Interferon Sensitivity-Determining Region of the Gene for Nonstructural Protein 5A Correlates with Interferon efficacy in Hepatitis C Virus Genotype 1b Infection. J Infect Dis 2001,183:1195-1203.
6丂Tazawa J, Maeda M, Sakai Y, Yamane M, Ohbayashi H, Kakinuma S, Miyasaka Y, Nagayama K, Enomoto N, Sato C: Radiation therapy in combination with transcatheter arterial chemoenbolization for hepatocellular carcinoma with extensive portal involvement. J Gastroenterol Hepatol 2001,16:660-665.
7丂Miyasaka Y, Enomoto N, Nagayama K, Izumi N, Marumo F, Watanabe M, Sato C. Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization. Br J Cancer 2001,85:228-34.
8丂Nakagawa M, Tazawa J, Sakai Y, Kakinuma S, Miyasaka Y, Ohbayashi H, Yamane M, Ikeda S, Shibata T, Sato C. Acute gastric mucosal lesions associated with cytomegalovirus infection in an immunocompetent adult. J Gastroenterol Hepatol 2001,16:842-3.
9丂Ohbayashi H, Tanaka Y, Ohoka S, Chinzei R, Kakinuma S, Goto M, Watanabe M, Marumo F, Sato C. TT virus is shown in the liver by in situ hybridization with a PCR-generated probe from the serum TTV-DNA. Journal of Gastroenterology & Hepatology 2001,16:424-8.
10 嶳嶈孫丆恄嶳弐揟丆愇尨僄儕僇丆悪塝崕柧丆栰帥攷巙丆嵅摗愮巎丗AIDS偵崌暪偟偨僒僀僩儊僈儘僂僀儖僗挵墛偺1朥専椺. 徚壔婍撪帇嬀 2001,13(8): 1233-1236.
11丂Chinzei R, Tanaka Y, Shimizu-Saito K, Hara Y, Kakinuma S, Watanabe M, Teramoto K, Arii S, Takase K, Sato C, Terada N, Teraoka H: Embryoid-body cells derived from a mouse embryonic stem cell line show differentiation into functional hepatocytes. Hepatology 2002,36:22-9.
12丂Ono K, Tanaka Y, Kusano F, Kakinuma S, Kozo Ishidate, Watanabe M, Marumo F, Sato C: Fas-ligand and perforin expression in infiltrating cytotoxic T lymphocytes in the liver of chronic hepatitis C. Hepatol Res 2002,23:153-62.
13丂壀揷塸棟巕丆抮揷棽柧丆搉曈廏庽丆戝壀恀栫丆抾撽姲丆懞忋晲巌丆惎栰桾帯丆搉曈庣丆嵅摗愮巎丗崿崌惈寢崌慻怐昦偲枬惈峛忬態墛傪崌暪偟偨帺屓柶塽惈娞墛偺1椺丏娞憻丂2002,43(5):232-7.
14丂Kakinuma S, Tanaka Y, Chinzei R, Watanabe M, Shimizu-Saito K, Hara Y, Teramoto K, Arii S, Sato C, Takase K, Yasumizu T, Teraoka H: Human umbilical cord blood as a source of transplantable hepatic progenitor cells. Stem Cell 2003,21:217-27.
15丂Watanabe H, Nagayama K, Enomoto N, Itakura J, Tanabe Y, Hamano K, Izumi N, Sato C.,Watanabe M. Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection. Virology 2003, 311:376-83.
16丂Watanabe H, Nagayama K, Enomoto N, Itakura J, Tanabe Y, Sato C, Izumi N, Watanabe M. Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy . Hepatol Res 2003,26:268-74.
17丂Ohoka S, Tanaka Y, Amako Y, Kohara K, Ishidate K, Watanabe M, Takahashi Y, Sato C. Sialadenitis in patients with chrinic hepatitis C is not directly related to hepatitis C virus. Hepatol Res 2003,27:23-9.
18丂Miyasaka Y, Enomoto N, Kurosaski K, Sakamoto N, Kanazawa N, Kohashi T, Ueda E, Maekawa S, Watanabe H, Izumi N, Sato C, Watanabe M: Hepatitis C virus NS5A protein inhibits TNF-alpha mediated apoptosis in Huh7 cells. J Infect Dis 2003 ,188:1537-44.
19丂Takenawa H, H, Kurosaki K, Enomoto N, Miyasaka Y, Kanazawa N, Sakamoto N, Ikeda T, Izumi N, Sato C, Watanabe M: Differential Gene Expression Profiles associated with Gastric Adenoma. Br J Cancer 2004,90:216-23.
20丂Ueda E, Enomoto N, Sakamoto N, Hamano K, Sato C, Izumi N, Watanabe M: Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hep Res 2004,29:89-96.
21丂Maekawa S, Enomoto N, Sakamoto N, Kurosaki M, Ueda E, Kohashi T, Watanabe H, Chen C-H, Yamashiro T, Tanabe Y, Kanazawa N, Nakagawa M, Sato C, Watanabe M: Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-14 isolate to replicate efficiently in Huh-7 cells. J Viral Hepatitis 2004,11:394-403.
22丂憹揷岝巌丆拞愳寬巌丆嵅摗愮巎丗擇娍帤岅傪尒弌偟岅偲偟偨堛妛弍屻妛廗帿揟嶌惉偺帋傒丏愱栧擔杮岅嫵堢尋媶丂2004,6:49-54.
23丂Chen CH, Nagayama K, Enomoto N, Miyasaka Y, Kurosaki M, Sakamoto N, Maekawa S, Kakinuma S, Ikeda T, Izumi N, Sato C, Watanabe M: Enhancement of mitochondrial gene expression in the liver of primary biliary cirrhosis. Hep Res 2005,31:24-30.
24丂Kikuchi K, Yoshida T, Kimata N, Sato C, Akiba T: Prevalence of hepatitis E virus infection in regular  hemodialysis patients. Ther Apher Dialy 2006,10:193-197.


<堛椕忣曬夝愅>

1丂Moriguchi H, Tazawa J, Hayashi Y, Takenawa H, Nakayama E, Marumooooo F, Sato C: Natural history of polypoid lesions of the gallbladder. Gut 39:860-862,1996.
2丂忋懞棽尦丆怷岥彯巎丆嵅摗愮巎丆戝慜榓岾丗曐寬僒乕價僗偺岠壥應掕摍昡壙偵娭偡傞尋媶丏暯惉11擭搙岤惗壢妛尋媶旓曗彆嬥丒寬峃壢妛憤崌尋媶帠嬈尋媶曬崘彂丏2000.
3丂Moriguchi H, Uemura T, Sato C. Evaluation of usefulness of qinolone and cepfems for acute upper respiratory tract infections. Int J Antimicrob Agents 2001, 72.
4丂Moriguchi H, Chung RT, Kobayashi M, Sato C. Management strategies for liver cirrhosis after resection of HCV-related early hepatocellular carcinoma: A decision analysis. Antiviral Ther 2002, 7 L 129.
5丂Moriguchi H, Sato C. Utility of number of amino acid mutations in the NS5A 2209-2248 region for sustained virological response to three interferon therapeutic regimens in patients with HCV-1b infection. Antiviral Ther 2002, 7 L 130.
6丂Moriguchi H, Uemura T, Kobayashi M, Chung RT, Sato C: Management strategies using pharmacologenomics in patients with severe HCV-1b infection: A decision analysis. Hepatology丂2002,36:177-85.
7丂Moriguchi H, Kobayashi M, Chung RT, Sato C: Optimal IFN therapy for 40-year-old patients with severe HCV-1b infection. Gastroenterology 2003,124:1166-7.
8丂Moriguchi H, Chung RT, Izumi N, Uemura T, Kobayashi M, Sato C: The interferon sensitivity determining region (ISDR) in the era of combination therapies and the rational use of combination therapies for the patients with HCV genotype 1b infection. Gastroenterology 2003,125:1284-6.
9丂Moriguchi H, Chung RT, Kobayashi M, Sato C: Tumor ablation plus interferon therapy for HCV-related early hepatocellular carcinoma: a meta-analysis of randomized controlled trial. Hepatology 2003,38 (Suppl):736A.
10丂Moriguchi H, Sato C: The values and limitations of Glypican-3 as a novel tumor marker for hepatocellular carcinoma from clinical and economic viewpoints. Gastroenterology 2004,127:679-680.
11  Moriguchi H, Kim TY, Sato C: Gefitinib for refractory advanced non small cell lung cancer. Lancet 2006,367:299-300.
12丂Moriguchi H, Uemura T, Sato C: Statin guidelines should give best statin. Brit Med J 2006,333:46.
13丂Moriguchi H, Uemura T, Sato C: The MEGA study. Lancet 2006,368:2052.


<寬峃嫵堢>

仜寬峃嫵堢
1丂嶰揷弮巕丆嵅摗愮巎丆挿扟晹壚巕丗崅峑惗偺惈奿婥幙偲怘枴巤峴丒怘昳歯岲偵娭偡傞専摙. 曐寬偺壢妛 2001,43(5):401-406.
2丂嬤摗壚戙巕丆姁扟桼壚丆嵅摗愮巎丗帺摦幵儗乕僒乕偺儗乕僗慜屻偺僗僩儗僗搙偵娭偡傞尋媶丏曐寬偺壢妛丂2002,44(4):313-8.
3丂巗愳晉旤巕丆懞揷撝巕丆姁扟桼壚丆崅揷奊棦巕丆嵅摗愮巎丗庒擭彈惈偺堸庰偵娭偡傞挷嵏尋媶-彈巕戝妛惗偺弶堸忬嫷偲偦偺屻偺栤戣堸庰峴摦偲偺娭楢丏曐寬晈嶨帍丂2003,59(3):238-42.
4丂嶳拞懽巕丆姁扟桼壚丆嵅摗愮巎丗C宆娞墛姵幰偺儔僀僼僗僞僀儖偲娞婡擻偺娭楢-惗妶妶摦嫮搙偲怘惗妶偐傜丏擔杮娕岇壢妛夛帍2003,23(2):32-9.
5丂Adachi Y, Sato C, Yamatsu K, Ito S, Adachi K, Yamagami T: A randomized controlled trial on the long-term effects of a 1-month behavioral weight control program assisted by computer tailored advice. Behav Res Ther 2007,45:459-470.
6丂朷寧岲巕丆嵅摗愮巎丗擔杮偲娯崙偵偍偗傞彫帣丒惵彮擭偺恎挿丒懱廳偺摦岦丏岞廜塹惗丂2007,71(10):880-884.
7丂Adachi Y, Sato C, Kunitsuka K, Hayama J, Doi Y: A brief behavior therapy administered by correspondence improves sleep-related behavior in poor sleepers. Biol Rhyth 2008,6:16-21.
8丂Adachi Y, Sato C, Hayama J: Late bedtime after 22 o'clock affects daily weight gain in 4-month-old infants. Sleep Biol Rhyth 2008,6:50-52.
9丂嵅媣娫梉旤巕丆嵅摗愮巎丗戝妛惗偺曐寬峴摦偲妶摦乗忬懺巜岦惈偺娭楢丏擔杮寬峃嫵堢妛夛帍丂2008,16(2):41-48.
10丂嵅媣娫梉旤巕丆桭摗桾旤丆媨撪惔巕丆嵅摗愮巎丗僠儑僐儗乕僩愛庢偑僐儞僺儏乕僞墘廗屻偺旀楯姶偵媦傏偡塭嬁丏擔杮寬峃堛妛夛帍丂2008,17(1):13-19.丂(懖嬈尋媶: 桭摗桾旤)
11丂敀栘桼壴丆媨撪惔巕丆嵅媣娫梉旤巕丆嵅摗愮巎丗儓乕僈偺崢捝偵懳偡傞岠壥丏擔杮寬峃堛妛夛帍(in press)乮懖嬈尋媶乯

仜欚殣偵娭偡傞尋媶
1丂搉曈媣丆姁扟桼壚丆擔壓榓戙丆崅揷奊棦巕丆嵅摗愮巎丆峳愳恀堦丆愇愳楏丆壛摗廏庽丆崅栰惓怣丗岥峯婡擻偍傛傃婰柫椡偵懳偡傞崅楊幰梡欚殣怘昳偺岠壥偵娭偡傞尋媶丏擔杮欚殣妛夛嶨帍 2003,13(1):37-43.
2丂壋娵徎悽丆姁扟桼壚丆搉曈媣丆擔壓榓戙丆壛摗廏庽丆崅栰惓怣丆嵅摗愮巎丗僌儈欚殣偑彫妛惗偺怱棟忬懺偍傛傃岥峯婡擻偵梌偊傞塭嬁偵娭偡傞尋媶丏擔杮欚殣妛夛嶨帍 2003,13(2):67-76.
3丂愇揷掑戙丗羼晈傊偺欚殣巜摫偑BMI尭彮丒寬峃傊偺娭怱丒晄埨娚榓偵偍傛傏偡岠壥丏偍拑偺悈堛妛夛帍丂2005,53(3, 4)81-22.
4丂愇揷掑戙丗擣抦峴摦椕朄傪妶梡偟偨羼晈傊偺挿婜欚殣巜摫偵娭偡傞柍嶌堊壔斾妑尋媶丏暯惉17亅19擭搙壢妛尋媶旓曗彆嬥丂婎斦尋媶乮C乯尋媶惉壥曬崘彂丏2008.乮嫟摨尋媶乯


<抧堟/嵼戭娕岇>

仜抧堟娕岇
1丂崟嶈徦巕丆姁扟桼壚丆嵅摗愮巎丗搶嫗俀俁嬫栶強偺夘岇曐尟傊偺懳墳丆幮夛曐尟弡曬2001,2091:32-35.
2丂忋揷夒巕丆姁扟桼壚丆嵅摗愮巎丗媫惈婜昦堾偵偍偗傞抧堟楢実傪悇恑偡傞偨傔偺愱栧晹彁偵娭偡傞暥專揑峫嶡丏恄屗巗娕岇戝妛婭梫 2004,8(3):45-57.
3丂忋揷夒巕丆姁扟桼壚丆堜忋朷丆抮揷惔巕丆嵅摗愮巎丗媫惈婜昦堾偺抧堟楢実晹彁偺幚懺偲暯嬒嵼堾擔悢傊偺塭嬁丏擔杮娕岇娗棟妛夛帍丂2005,8(2):30-36.
4丂晉壀彫昐崌丆愇郪宐丆戝抾傑傝巕丆愒娫柧巕丆嵅摗愮巎丆楅栘堢巕丆彫椦弤巕丆姁扟桼崄丗朘栤娕岇巘偺怑柋枮懌搙偵娭楢偡傞梫場丏擔杮嵼戭働傾妛夛帍丂2007,11(1):43-51.
5丂戝抾傑傝巕丆峳堜岾巕丆栴岥桾巕丆釼摗柧巕丆姁扟桼壚丆彫椦弤巕丆拞愳孫丆釼摗僇僣巕丗乽傑偪偺曐寬幒乿偵懳偡傞抧堟廧柉偺擣幆偲棙梡忬嫷丆戞37夞擔杮娕岇妛夛榑暥廤亅抧堟娕岇亅2007,158-160.

仜嵼戭娕岇
1丂Yonezawa H, Takasaki K, Teraoka K, Asaka T, Sato C,Tsuchiya K: Effect of tongue and oral mucosa cleaning on oral candida species and production of volatile sulfur compounds in the elderly in a nursing home. J Med Dent Sci 2003,50:1-8.
2丂愇愳傝傒巕丗屇媧崲擄傪桳偡傞枬惈屇媧婍幘姵姵幰偺嵼戭椕梴宲懕偲偵娭偡傞尋媶丏偍拑偺悈堛妛夛帍丂2005,53(1, 2):1-22.
3丂忛撪宨巕丆抮揷惔巕丆拞郪恗旤丆楅栘堢巕丆姁扟桼壚丆嵅摗愮巎丗嵼戭堛椕廔枛婜偺娕庢傝偵娭偡傞壠懓偺枮懌搙偵偮偄偰亅娕庢傝偺応強乿乽堄巙偺懜廳乿乽嬯捝偺娚榓乿乽堦弿偵夁偛偟偨帪娫乿偵徟揰傪偁偰偰亅丏恄屗巗娕岇戝妛婭梫丂2008,12:37-43.

仜戅堾巟墖偵娭偡傞尋媶
1丂姁扟桼壚丗昦搹偵偍偗傞僋儕僥傿僇儖僷僗朄偺摫擖偵娭偡傞尋媶乚姵幰偺憗婜夞暅丆憗婜戅堾偵懳偡傞娕岇怑偺堄幆傊偺塭嬁乚丏偍拑僲悈堛妛嶨帍丂2002,50(1):25-36.
2  姁扟桼壚丆戝抾傑傝巕丆揷戙惓抝丆堜郪徠旤丆嵅摗梞巕丆嵵摗柧巕丆彫椦弤巕丆嵅摗愮巎丗摿掕婡擻昦堾偵偍偗傞戅堾巟墖偺偨傔偺憗婜僗僋儕乕僯儞僌曽朄偵娭偡傞尋媶丏丂暯惉16擭搙堛椕宱嵪尋媶婡峔曬崘彂丆2005.
3丂怷尞桽巕丆姁扟桼崄丆戝抾傑傝巕丆愒娫柧巕丆楅栘堢巕丆彫椦弤巕丆揷戙媣抝丆嵅摗愮巎丗摿掕婡擻昦堾偵偍偗傞憗婜戅堾巟墖傪栚揑偲偟偨僗僋儕乕僯儞僌昜偺摫擖偍傛傃懨摉惈丏擔杮娕岇尋媶妛夛丂2007,31(4)27-36.
4丂戝抾傑傝巕丆揷戙媣抝丆堜郪徠旤丆嵅摗梞巕丆愒娫柧巕丆楅栘堢巕丆彫椦弤巕丆嵶扟偨偒巕丆嵅摗愮巎丆栘懞棟丆姁扟桼壚丗摿掕婡擻昦堾偵偍偗傞昦搹娕岇巘偺敾抐傪婎偵偟偨戅堾巟墖僗僋儕乕僯儞僌崁栚偺専摙丏嶳宍堛妛2008,26(1):11-23.


<娕岇娗棟>

仜娕岇娗棟
1 揷拞棦崄丆姁扟桼壚丆拞嶳塰弮丆嵅摗愮巎丗拞彫婯柾昦堾偵偍偗傞娕岇怑偺儐僯僼僅乕儉岎姺昿搙偲娕岇娗棟幰偺巜摫偵娭偡傞尋媶乚愮梩導偺挷嵏傛傝乚丆擔杮娕岇尋媶妛夛嶨帍2001,24(4):69-76.
2 姁扟桼壚丆娕岇怑庡摫偺昦搹偵偍偗傞姵幰偺墖彆僯乕僘暿偺僋儕僥傿僇儖僷僗朄摫擖偵娭偡傞尋媶乚娕岇怑怑柋枮懌搙丆姵幰枮懌搙丆嵼堾擔悢傊偺塭嬁乚丆暯惉12擭搙惞儖僇丒儔僀僼僒僀僄儞僗尋媶強乽椪彴塽妛尋媶側偳偵娭偡傞尋媶彆惉乿尋媶曬崘彂丆2001.
3丂媑嶳埄丆姁扟桼壚丆嵅摗愮巎丗娕岇晈乛巑偐傜娕岇巘傊偺柤徧曄峏偵傛傞娕岇怑偵懳偡傞堦斒恖偺僀儊乕僕偺曄壔丏娕岇娗棟丂2003,13(12):1010-7.
4丂弌塇宐巕丆姁扟桼壚丆嵅摗愮巎丗昦堾偺尵梩尛偄偵懳偡傞巜摫偲娕岇怑偺尵梩尛偄偵懳偡傞姵幰偺擣幆偲枮懌搙丏擔杮娕岇尋媶妛夛帍丂2004,27(4):101-107.
5丂嵅摗堢巕丆嵅乆栘乮壋娵乯徎悽丆憗旜峅巕丆嵅摗愮巎丗娕岇巘偵偍偗傞僗僩儗僗偲敡峳傟偲偺娭學丏寧姧僫乕僔儞僌 2006,26(9):98-103. 乮懖嬈尋媶乯
6丂徏杮嵤巕丆嵅媣娫梉旤巕丆杧愳嵐怐丆廰堜桪丆惵栘憗怐丆嶳娸徦巕丆嵅摗愮巎丗僫乕僗偺庻柦亅娕岇宯戝妛偲堦斒彈巕戝偲偺斾妑亅丏丂曐寬偺壢妛丂(in press)丂(懖嬈尋媶)


仜憗婜棧怑/ 僶乕儞傾僂僩丒傾僒乕僥傿僽僱僗偵娭偡傞尋媶
1丂楅栘塸巕丆姁扟桼壚丆杒壀乮搶岥乯榓戙丆嵅摗愮巎丗戝妛昦堾偵嬑柋偡傞怴懖娕岇怑偺怑応娐嫬媦傃傾僒乕僥傿僽僱僗偲僶乕儞傾僂僩儕僗僋丏擔杮娕岇尋媶妛夛帍丂2005,28(2)89-102.
2丂楅栘塸巕丗娕岇巘偺僶乕儞傾僂僩偲傾僒乕僥傿僽側帺屓昞尰偵娭偡傞尋媶乮怴懖娕岇怑偺僶乕儞傾僂僩偲憗婜棧怑乯丏暯惉15擭搙-暯惉17擭搙壢妛尋媶旓曗彆嬥曬崘彂丏2006丏
3丂Suzuki E,Itomine I, Kanoya Y, Katsuki T, Horii S, Sato,C: Factors affecting rapid turnover of novice nurses in university hospitals. J Occup Hlth 2006,48:49-61.乮攷巑榑暥乯
4丂Suzuki E, Kanoya Y, Katsuki T, Sato,C:Assertiveness Affecting Burnout of Novice Nurses at University HospitalsJpn J Nurs Sci 2006,3:93-105.
5  峳愳愮廐丆嵶愳弤巕丆彫嶳撪桼婓巕丆姁扟桼壚丆嵅摗愮巎丗戝懖怴恖娕岇巘偺巟墖偺偁傝曽偵娭偡傞尋媶丏擔杮娕岇娗棟妛夛帍 2006,10(1):37-43.
6丂巺椾堦榊丆楅栘塸巕丆姁扟桼壚丆嵅摗愮巎丗戝妛昦堾偵嬑柋偟偨怴懖娕岇怑幰偺儕傾儕僥傿僔儑僢僋偵娭偡傞梫場丏擔杮娕岇尋媶妛夛帍2006,29(4):63-70.
7丂楅栘塸巕丆嵵摗怺愥丆娵嶳徍巕丆屷嵢抭旤丆崄寧婤巎丆嵅摗愮巎丗娕岇娗棟怑偺Rathus Assertiveness Schedule丂乮J-RAS乯偺怣棅惈偲懨摉惈偺専摙丏擔杮曐寬暉巸妛夛帍丂2007,14(1):33-41.
8丂楅栘塸巕丗娕岇巘偺僶乕儞傾僂僩偲傾僒乕僥傿僽側帺屓昞尰偵娭偡傞尋媶丏暯惉15-17擭搙壢妛尋媶旓曗彆嬥乮婎斦尋媶乮俠乯乮2乯乯尋媶惉壥曬崘彂乮壽戣斣崋15592343乯2007. 乮嫟摨尋媶乯
9丂Suzuki E, Itomina I, Saito M, Katsuki T, Sato C: Factors affecting the turnover of novice nurses at university hospitals: A two year longitudinal study. Jpn J Nurs Sci 2008, 5:9-21.


<娕岇嫵堢>

1丂媨嶁旤斂丆擔壓榓戙丆姁扟桼壚丆拞嶳塰弮丗屒撈姶偐傜傒偨尰戙堛椕宯戝妛惗偺恖娫娭學偺幚懺丆娕岇嫵堢2001,42(12):1116-1121.
2丂搉曈旤崄丆愇堜愮宐丆嵅摗愮巎丆挿扟晹壚巕丗懖嬈傪峊偊偨娕岇妛惗偺怑嬈娤-戝妛偲愱栧妛峑偺斾妑丏娕岇嫵堢丂2003,44(3):236-41.
3丂姁扟桼壚丆彫愹恗巕丆擔壓榓戙丆愮梩桼旤丆擇媨嵤巕丆惔悈惔旤丆怷揷媣旤巕丆壀岝婎巕丆彫扟栰峃巕丆栴晉桳尒巕丆撪杧恀媩丆媨杮恀枻丗椪抧幚廗偵偍偗傞奺椞堟嫟捠偺娕岇媄弍僠僃僢僋儕僗僩摫擖偺帋傒丏娕岇嫵堢2003,44乮12乯:1030-9.
4丂惸摗旤壺丆怷尞桽巕丆愳尨楃巕丗嫵堳偑崅楊幰栶傪墘偠傞儘乕儖僾儗僀儞僌墘廗偵偍偗傞妛惗偺妛傃乕崅楊幰偲偦偺壠懓傪懳徾偲偟偨奜棃娕岇巘偺栶妱偵徟揰傪摉偰偰乕丏偺昳榁擭娕岇妛夛帍2006,11(1):53-61.
6丂嬍忛惔巕丆夑悢偄偯傒丗庒擭擠晈偺戀帣傊偺垽拝偵娭楢偡傞梫場偺専摙丏壂撽導棫娕岇戝妛婭梫丂2006,7 (March):10-16.
7丂暯堜偝傛巕丗娕岇怑偺愱栧怑揑帺棩惈偲宲懕嫵堢傊偺庢傝慻傒偵娭偡傞擔拞斾妑尋媶丏暯惉16-18擭搙壢妛尋媶旓曗彆嬥乮婎斦尋媶乮俠乯乮2乯乯尋媶惉壥曬崘彂乮壽戣斣崋16592124乯2007.乮嫟摨尋媶乯
8丂怷尞桽巕丆嵵摗旤壺丆愳尨楃巕丗榁擭娕岇偵偍偗傞嫵堳偑懳徾幰栶傪墘偠傞儘乕儖僾儗僀儞僌墘廗偺堄媊偺専摙丏杒擔杮娕岇妛夛帍丂2007,9(2):46-52.
9丂Kuroda T, Kanoya Y, Sasaki A, Katsuki T,, Sato C: Education programs, preceptorship, and the anxiety of novice nurses in midsize hospitals in Japan. J Contin Educ Nurs丂2008. (in press)乮懖嬈尋媶乯
10 怷尞桽巕丆釼摗旤壺丆愳尨楃巕丗壠懓娕岇妛傪妛廗偟偨妛惗偺嫽枴謵S偺曄壔 嫵堳偑墘偠傞儘乕儖僾儗僀儞僌墘廗傪捠偟偰丏杒擔杮娕岇妛夛帍 2008,10(2):33-40.
11 怷尞桽巕丆釼摗旤壺丆愳尨楃巕丗娕岇妛惗偑崅楊幰偲惗妶偡傞偲偒偵婥傪偮偗偨偄偙偲 僥僉僗僩夝愅偵傛傞帺桼婰弎偺暘愅丏搶杒戝妛堛妛晹曐寬妛壢婭梫2008,17(1) (in press)


<惛恄娕岇>

1丂擔壓榓戙丆姁扟桼壚丗惛恄忈奞幰偺憗婜戅堾傪栚巜偟偨帯椕丒娕岇偺昗弨壔偵娭偡傞尋媶乚僋儕僥傿僇儖丒僷僗朄傪梡偄偰乚丏暯惉13擭搙惞儖僇丒儔僀僼僒僀僄儞僗尋媶強乽椪彴塽妛尋媶側偳偵娭偡傞尋媶彆惉乿尋媶曬崘彂2002.
2丂曅嶳憦巕丆姁扟桼壚丆擔壓榓戙丆嵅摗愮巎丗惛恄忈奞幰彫婯柾嶌嬈強捠強幰偺Quality of Life偵娭偡傞尋媶-惗妶枮懌搙偵徟揰傪偁偰偰-丏擔杮娕岇尋媶妛夛帍丂2003,26(1):147-61.
3丂敿揷旤怐丆姁扟桼壚丆擔壓榓戙丆嵅摗愮巎丗僨僀働傾偵捠強偡傞惛恄忈奞幰偺惗妶枮懌姶偵娭偡傞尋媶丏擔杮娕岇壢妛妛夛帍 2004, 23(1):20-30.
4丂崄寧婤巎丆姁扟桼壚丆楅栘塸巕丆嵅摗愮巎丗僥儘儕僘儉偑TV儊僨傿傾傪攠懱偲偟偰堦斒巗柉偵梌偊傞惛恄揑塭嬁偺暥專揑峫嶡丏惛恄堛妛 2004,46(5):493-503.
5丂Kusaka K, Kanoya Y, Sato C: Effects of introducing a critical care path method to standardize treatment and nursing for early discharge from acute psychiatry unit. J Nurs Managem 2005.
6丂崄寧婤巎丆嶳杮榓宐丆嵅摗愮巎丗僥儘儕僘儉偵偍偗傞惛恄揑塭嬁偵偮偄偰偺暥專揑峫嶡丏忋晲戝妛娕岇妛晹婭梫 2006,1:51-66.
7丂Kusaka K, Kanoya Y, Sato C: Effects of introducing a critical care path method to standardize treatment and nursing for early discharge from acute psychiatry unit. J Nurs Manag 2006,14:69-80. 乮攷巑榑暥乯
8丂崄寧婤巎丆嶳杮榓宐丆嵅摗愮巎丗僥儘儕僘儉偵偍偗傞惛恄揑塭嬁偵偮偄偰偺暥專揑峫嶡丏忋晲戝妛娕岇妛晹婭梫 2006,1:51-66.
9丂崄寧婤巎丆楅栘塸巕丆嵅摗愮巎丗崅楊幰夘岇巤愝偵偍偗傞偙偺摼忈奞傪帩偭偨擣抦徢姵幰偺傾僙僗儊儞僩乕僑乕僪儞偺婡擻揑寬峃僷僞乕儞偺桳岠棙梡乗丏擔杮曐寬暉巸妛夛帍丂2007,13(2):29-35.


<曣惈娕岇>

仜曣惈娕岇
1丂忋堜柅巕丆嵅摗愮巎丗暘曍帪偺屇媧儁乕僗桿摫偵娭偡傞弨柍嶌堊壔斾妑帋尡丏曣惈塹惗丂2000, 41(2): 307-311. (廋巑榑暥)
2丂墍晹恀旤丆忋揷楃巕丗嶻羼弶婜偵偍偗傞梴堢忋偺僴僀儕僗僋曣巕偺憗婜敪尒偲巟墖 -庼擕応柺偵偍偗傞憡屳嶌梡- 丏曣惈塹惗丂2000,41(2):312-318. (廋巑榑暥)
3丂扟岥愮奊丗塣摦廗姷偺側偄擠晈偵偍偗傞曕峴偲擠怭拞偺婥暘偺曄壔媦傃弌嶻偲偺娭楢丏偍拑僲悈堛妛嶨帍丂2002,50(1):55-61.
4丂墍晹恀旤丗擠怭偵傛傞晝恊偺堸庰丒媔墝偺峴摦曄壔偲嶻屻侾儢寧偵偍偗傞巕偳傕偺庴偗巭傔偺娭楢丏偍拑僲悈堛妛嶨帍丂2002,50(4):157-66.
5丂壨揷傒偳傝丆悪壓抦巕丆嵅摗愮巎丗暘曍巤愝偺彆嶻巘偵傛傞怴惗帣朘栤傊偺僯乕僘乕擕帣寬恌庴恌幰偵偍偗傞挷嵏偐傜乕丏曣惈塹惗 2004, 45(1):20-27丏
6丂怴堜崄棦丆嵅乆栘乮壋娵乯徎悽丆嵅摗愮巎丗奜崙恖擠嶻晈偵懳偡傞嶻壢昦搹偺懳墳丏彆嶻嶨帍 2006, 60(4):355-360. 乮懖嬈尋媶乯
7丂驸渑丆嵅乆栘乮壋娵乯徎悽丆嵅摗愮巎丗晄擠帯椕傪庴偗偨擠晈偺晄埨媦傃懳帣姶忣偲帯椕攚宨丏擔杮彆嶻妛夛帍丂20(1)99-106. 乮廋巑榑暥乯
8丂嬍忛惔巕丆忋揷楃巕丗庒擭曣恊偺怴惗帣偵懳偡傞抦妎偲堢帣峴摦丆壂撽導棫娕岇戝妛婭梫丂2007,8:8-15.
9丂朷寧岲巕丗弌惗懱廳偲巚弔婜偺懱奿丒寬峃擣幆偵塭嬁傪媦傏偡梫場丏偍拑偺悈堛妛夛帍(in press)乮攷巑榑暥乯

仜彈惈偺怱恎偺寬峃/ 寧宱偵娭偡傞尋媶
1丂嵅媣娫梉旤巕丆姁扟桼崄丆愇岝晣旤巕丆嵶柤悈惗丆朷寧岲巕丆嵅摗愮巎丗庒擭彈惈偺寧宱慜婜偍傛傃寧宱婜徢忬偵塭嬁傪媦傏偡梫場亅娕岇妛惗偲愱栧妛峑惗偵偍偗傞惗妶廗姷丒曐寬峴摦偺斾妑丏擔杮娕岇尋媶妛夛帍 2008,31(2):25-36.
2丂嵅媣娫梉旤巕丆姁扟桼崄丆嵅摗愮巎丗怴擖彈巕妛惗偺擔忢惗妶偺曄壔偑寧宱廃婜偵敽偆徢忬偵媦傏偡塭嬁丏曣惈塹惗2008,49(2):286-294丏
3丂媨撪惔巕丆朷寧岲巕丆愇揷掑戙丆嵅摗愮巎丗拞崅擭彈惈偺廇嬈宍懺偲峏擭婜徢忬偺娭楢丏曣惈塹惗 49(4) (in press)
4丂媨撪惔巕丆朷寧岲巕丆愇揷掑戙丆嵅摗愮巎丗拞崅擭彈惈楯摥幰偺僗僩儗僗懳張摿惈偍傛傃峏擭婜徢忬偲梷偆偮偺娭楢丏擔杮峏擭婜妛夛帍丂2008,16(2) (in press)
5丂惔悈惔旤丗寧宱慜徢岓孮偵懳偡傞傾儘儅僥儔僺乕偺岠壥乗恷巁儕僫儕儖乮Linalyl acdetate乯偺専徹乗丏偍拑偺悈堛妛夛帍丂2008,56(1):15-26.乮攷巑榑暥乯


<惉恖娕岇>

仜媫惈婜/ 惉恖娕岇
1丂姁扟桼壚丆嵅摗愮巎丗擜楬棷抲僇僥乕僥儖偲拁擜僶僢僌偺岎姺昿搙偵懳偡傞昦搹撪婎弨偲娕岇怑偺岼娫偺幚嵺丏擔杮娕岇尋媶妛夛帍 2004,27(1):101-105.
2丂媣暷悏丆姁扟桼壚丆嵅摗愮巎丗媬柦媬媫僙儞僞乕ICU偵擖幒偟偨姵幰偺晄埨偲僗僩儗僗偵娭偡傞尋媶丏擔杮娕岇尋媶妛夛帍丂2004,27(5):93-99.
3丂媣暷悏丗媫惈怱嬝峓嵡姵幰偵懳偡傞憗婜儕儔僋僙乕僔儑儞僾儘僌儔儉偺岠壥丏偍拑偺悈堛妛夛帍 2006,54(3):101-111. 乮攷巑榑暥乯
4丂愇岝晣旤巕丆姍憅傗傛偄丆怺揷弴巕丗弍屻偣傫栂慜嬱徢忬娤嶡僣乕儖奐敪偵娭偡傞婎慴揑尋媶乗弍屻偣傫栂徢忬偺峔憿壔丏擔杮娕岇壢妛妛夛帍 2006,26(4):74-83.
5丂嵶柤悈惗丆媣暷悏丆嵅媣娫梉旤巕丆嵅摗愮巎丗怱憻僇僥乕僥儖専嵏傪庴偗傞姵幰偺晄埨偲嬯捝偵娭偡傞尋媶乗夁嫀10擭娫偺暥專揑峫嶡丏僴乕僩僫乕僔儞僌丂2007,20(7):94-100.
6丂嵶柤悈惗丗怱憻僇僥乕僥儖専嵏偺姵幰偵懳偡傞専嵏愢柧儕儔僋僙乕僔儑儞僾儘僌儔儉偺岠壥丏偍拑偺悈堛妛夛帍丂2007,55(1,2,3):1-12.乮攷巑榑暥乯

仜羼憂偵娭偡傞尋媶
1丂姁扟桼壚丆徖揷旤岾丆摗尨懽巕丗羼釋傪桳偡傞朘栤娕岇働傾偺僋儕僥傿僇儖僷僗朄摫擖偵傛傞岠壥乚羼釋偺帯桙偲娕岇晈偺堄幆偵徟揰傪摉偰偰乚丆暯惉12擭搙戞俇夞朘栤娕岇丒嵼戭働傾尋媶彆惉帠嬈曬崘彂2001, p27-34.
2丂姁扟桼壚丆徖揷旤岾丆摗尨懽巕丆擔壓榓戙丆嵅摗愮巎丗羼釋傪桳偡傞姵幰傊偺朘栤娕岇働傾偺僋儕僥傿僇儖僷僗朄摫擖偵傛傞岠壥-羼釋帯桙偲娕岇怑偺抦幆傊偺塭嬁-丏擔杮羼釋妛夛帍丂2002,4(1):96-104.
3丂姁扟桼壚丆塱揷栁庽丆郪嶳岾宐丆擔壓榓戙丆嵅摗愮巎丗羼釋偵懳偡傞億儕僼僃僲乕儖揧壛惗棟怘墫悈偵傛傞愻忩偺岠壥偵娭偡傞尋媶丏擔杮羼釋妛夛帍丂2003,5(1):67-71.

仜摟愅姵幰偺娕岇偵娭偡傞尋媶
1丂Nakayama E, Liu J-h, Akiba T, Marumo F, Sato C: Low prevalence of anti-hepatitis C virus antibodies in female hemodialysis patients without blood transfusion: a multicenter analysis. J Med Virol 48:284-288, 1996.
2丂Nakayama E, Akiba T, Marumo F, Sato C: Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephorol 11:1896-1902,2000.
3丂揷岥捈旤丆挿扟晹壚巕丆嶳拞懽巕丆晲媣峅巕丆拞嶳塰弮丆嵅摗愮巎丄廐梩棽丄娵栁暥徍丄孖尨楀丄彫妢尨梲丗摟愅姵幰偺椃峴巟墖偵偮偄偰丏摟愅夛帍 2000, 33(6):1053-1058.
4丂惓壀乮崀婙乯弮巕丆嵅乆栘乮壋娵乯徎悽丆崄寧婤巎丆廐梩棽丆嶁杮椣旤丆廰扟棟宐丆嵅摗愮巎丗帩懕揑暊枌摟愅姵幰偵偍偗傞塣摦偑怱棟忬懺偵媦傇憙塭嬁丏摟愅僕儍乕僫儖丂2005,11(5):110-115.
5丂釼摗旤壺丆怷尞桽巕丆彫栰偁偮巕丆愳尨楃巕丗崅楊摟愅姵幰偺擔忢惗妶偺廩幚姶偲帺屓岠椡姶偍傛傃摟愅僐儞僩儘乕儖忬嫷偵娭偡傞尋媶丏搶杒戝妛堛妛晹曐寬妛壢婭梫 2008,17(1) (in press)

仜忈奞傪傕偮姵幰偺娕岇偵娭偡傞尋媶
1丂惔悈桼崄棦丆姁扟桼壚丆嵅摗愮巎丗挳妎忈奞幰偺堛椕婡娭庴恌帪偺晄埨偲幚嵺偺昦堾偺懳墳丏娕岇娗棟 2005,15(1):20-23.
2丂惵栘憗怐丆嵅媣娫梉旤巕丆嶳娸徦巕丆徏杮嵤巕丆杧愳嵐怐丆廰堜桪丆嵅摗愮巎丗帇妎忈奞幰偺娕岇嘥亅帇妎忈奞幰偺娕岇偵娭偡傞暥專揑専摙丏娽壢働傾丂2008,10(6):106-111.乮懖嬈尋媶乯
3丂惵栘憗怐丆嵅媣娫梉旤巕丆嶳娸徦巕丆徏杮嵤巕丆杧愳嵐怐丆廰堜桪丆嵅摗愮巎丗帇妎忈奞幰偺娕岇嘦亅丏娽壢働傾(in press)乮懖嬈尋媶乯


<偦偺懠>

仜広搙奐敪偵娭偡傞尋媶
1丂楅栘塸巕丆姁扟桼壚丆愇揷掑戙丆崄寧婤巎丆嵅摗愮巎丗擔杮岅斉Rathus assertiveness schedule 奐敪偵娭偡傞尋媶丏擔杮幮夛暉巸妛夛帍丂2004,10(2):19-29.
2丂楅栘塸巕丆姁扟桼壚丆杧堜偝傗偐丆崅揷奊棦巕丆杒壀乮搶岥乯榓戙丆嵅摗愮巎丗擔杮斉BMI (Maslach Burnout Inventory) 偺幚梡惈偺専摙丏擔杮娕岇尋媶妛夛帍丂2004,27(4):85-90.
3丂Suzuki E, Kanoya Y, Katsuki T, Sato,C: Verification of reliability and validity of a Japanese version of the Rathus Assertiveness Schedule. J Nurs Manag 2006,14:1-9.
4丂Suzuki E, Kanoya Y, Katsuki T, Sato,C: Verification of reliability and validity of a Japanese version of the Rathus Assertiveness Schedule. J Nurs Manag丂2007,丂15:530-537.
5丂嵅媣娫梉旤巕丆嵅摗愮巎丗擔杮岅斉Action Control Scale (ACS90)偺嵞僥僗僩怣棅惈偲撪揑懨摉惈偺専摙丏擔杮寬峃嫵堢妛夛帍丂2008,16(1):3-10.



亂 憤愢丒挊彂亃
1丂Nagayama K, Enomoto N, Sato C: Clinical aspects of hepatitis C virus mutation. Res Devel Virol 1999,1:891-895.
2丂忋堜柅巕, 嵅摗愮巎:丗椪彴偱EBM傪偡偡傔傞偨傔偵 -Evidence傪傔偖傞岆夝傪偲偔丏娕岇妛嶨帍丂2000,64(7):634-638.
3丂扟岥愮奊丆嵅摗愮巎丗奜崙恖擠嶻晈丏側偵偑栤戣側偺偐-擔杮偺尰忬傪傒傞丏彆嶻晈嶨帍 2000, 54(8):14-16.
4丂媨愳敧暯丆嵅摗愮巎丗傾儖僐乕儖惈娞忈奞偲僂傿儖僗姶愼丏娞抇鋁丂2000, 40(1):45-50.
5丂廐梩棽丆嶳嶈恊梇丆廐郪拤抝丆嵅摗愮巎丆媑郪峗巌丗寣塼摟愅椕朄偵偍偗傞堾撪姶愼杊巭懳嶔偺尰嫷丏摟愅夛帍丂2000, 33:1303-1312.
6丂嵅摗愮巎丗HCV抈敀偺IRES埶懚惈抈敀東栿婡峔偵媦傏偡塭嬁. 擔杮椪彴 2001,59(7):1271-1276.
7丂嵅摗愮巎丗娞墛僂僀儖僗偺摦懺丆曄堎偲偦偺椪彴揑堄媊乕C宆娞墛. Medical Practice 2001,18(1):49-53.
8丂嵅摗愮巎丗僂僀儖僗惈枬惈娞墛乮帯椕偺尰忬偲栤戣揰乯. 枅擔儔僀僼 2寧崋乮摿廤丗娞憻昦傪帯偡嵟慜慄乯2001,pp32-36.
9丂嵅摗愮巎丆暯揷傝偊丗撪壢妛. 尵岅挳妎忈奞妛乮愇崌弮晇曇挊乯丆怴嫽堛妛弌斉幮丆搶嫗 2001,pp50-58.
10丂抮揷棽柧丆惎栰桾帯丆壀揷塸棟巕丆搉曈廏庽丆戝壀恀栫丆抾撽姲丆懞忋晲巌丆嵅摗愮巎丗栻嵻惈娞忈奞偺恌抐乕僼儘乕僒僀僩儊僩儕乕偵傛傞儕儞僷媴巋寖帋尡. 嵟怴娞憻昦妛乮搉曈柧帯丆旙岥惔攷曇挊乯丆怴嫽堛妛弌斉幮丆搶嫗 2001,pp79-83.
11丂嵅摗愮巎丗摐擜昦姵幰偺娕岇. 椪彴娕岇 2001,27(3):301-302.
12丂崱揷憦抝丆崅岝媊攷丆挿扟愳淎暥丆堫杮尦丆娭揷寷堦丆嵅摗愮巎丆椦弮丆戝墥塸堦丗摟愅姵幰偺姶愼梊杊丂摟愅夛帍丂2001,34(6):1063-1069.
13丂擇媨嵤巕丆嵅摗愮巎丗暊晹. 乮摿廤丗僼傿僕僇儖傾僙僗儊儞僩偺偨傔偺夝朥丒惗棟妛乯丆椪彴娕岇 2001,27(13):1965-1982.
14丂媑壀巙捗巕丆嵅摗愮巎丗姶愼娗棟偲僄價僨儞僗丗婍嵽娗棟乕棷抲僇僥乕僥儖偺娗棟. EBNursing 2001,1(2):20-22.丂
15丂姁扟桼壚丗朘栤娕岇傊偺僋儕僥傿僇儖僷僗朄偺揔梡丆擄昦偲嵼戭働傾2001,7(2):59-63.
16丂姁扟桼壚丗羼釋姵幰偺僋儕僥傿僇儖僷僗丆椪彴娕岇 2001,27(9):1414-1421.
17丂嶳拞懽巕丆姁扟桼壚丆擔壓榓戙丆嵅摗愮巎丗暥專儗價儏乕 僋儔僀僄儞僩偺朷傑偟偄傾僂僩僇儉偺昡壙巜昗 QOL丆ADL丆惛恄丒怱棟広搙儗價儏乕丆娕岇娗棟 2001,11(9):704-711.
18丂姁扟桼壚丗戞22夞ICN僐儁儞僴乕僎儞戝夛 婎挷島墘:峴摦傊偺怴悽婭Virginia Henderson捛搲島墘丆娕岇妛嶨帍 2001,65(120):898-903.
19丂姁扟桼壚丗戞22夞ICN係擭枅戝夛儕億乕僩乽僙僢僔儑儞乿擬怱偵丆榓傗偐偵媍榑偝傟偨娕岇娗棟丆娕岇2001,53(11):48-49.
20丂姁扟桼壚丗昦搹偵崌偭偨娕岇曽幃傪峫偊傞丆寧姧僫乕僗僨乕僞2001,22(11):11-16.
21丂姁扟桼壚丗嵟怴娕岇娗棟梡岅帠揟丏娕岇娗棟梡岅専摙埾堳夛曇丆擔憤尋弌斉丆柤屆壆丆2001.
22丂姁扟桼壚丗羼釋偺偡傋偰丏媨抧椙庽丆恀揷峅旤娔廋丆塱堜彂揦丆搶嫗丆2001.
23丂嵅摗愮巎丗HCV峈懱堿惈壔偺尨場専嶕丏擔杮堛帠怴曬丂2001,4029:107-108.
24丂嵅摗愮巎丗僂僀儖僗娞墛乮B宆丆C宆乯丏摟愅椕朄偺儕僗僋儅僱乕僕儅儞僩乮斞揷婌弐丆廐郪拤抝丆捴尨旤帯曇挊乯拞奜堛妛幮丆搶嫗2002, pp266-272.
25丂嵅摗愮巎丆擇媨嵤巕丗僴僀儕僗僋姵幰偺栻暔椕朄丟娞忈奞姵幰丏娕岇偺偨傔偺嵟怴堛妛島嵗戞28姫丗栻暔椕朄乮埨尨崃恖曇廤乯拞嶳彂揦丆搶嫗丆2002, pp53-57.
26丂嵅摗愮巎丆擇媨嵤巕丗娞丒抇丒鋁帯椕栻丏僐儊僨傿僇儖偺帯椕栻儅僯儏傾儖乮撧椙怣梇曇挊乯拞奜堛妛幮丆搶嫗丆2002, pp281-300.
27丂嵅摗愮巎丗僼傽僕乕側寬峃偲惗妶廗姷昦丏椪彴娕岇丂2002,28(7):1003-1003.
28丂嵅摗愮巎丗枬惈娞墛偺尨場摨掕偐傜専嵏朄妋棫傑偱丏尰戙偺娞幘姵丏憤崌椪彴 2002,51(6):1935-1939.
29丂嵅摗愮巎丗偑傫偽傞偁側偨偺寬峃僋儕僯僢僋乽C宆娞墛乿丏寧姧ABC乮挬擔惗柦宱塩忣曬儅僈僕儞乯 2002,3寧崋26-27.
30丂扟岥愮奊丆嵅摗愮巎丗擠怭婜偲惗妶廗姷昦丏 椪彴娕岇丂2002,28(7):1085-8.
31丂姁扟桼壚丆嵅摗愮巎丆拞嶳塰弮丆挿扟晹壚巕丗娕岇晈乛巑偐傜娕岇巘傊丆娕岇怑偵栤傢傟傞怴偟偄僀儊乕僕 僫乕僗僉儍僢僾偺帩偮堄媊偲娕岇怑偺堄幆偺曄慗丆娕岇娗棟丂2002,12(4):292-6.
32丂擔壓榓戙丆姁扟桼壚丆愹戲掕巕丆愇奯夒擵丆惣愳棩巕丆戝孖捈旤丆媑嶈榓旻丆嵵摗抭巕丆徏嶁恀斳巕丆埳戲僉僋僄丆揤夑扟棽丆摗栰儎儓僀丗惛恄壢偵偍偗傞僋儕僥傿僇儖僷僗偺崱丆寧姧僫乕僗僨乕僞丂2002,23(2):33-7.
33丂姁扟桼壚丗乽娕岇惂搙偵娭偡傞尋媶?曐寬晈彆嶻晈娕岇晈朄偺夵惓偵岦偗偰娕岇嬈柋傪峫偊傞乕乿乮戞侾復 娕岇嬈柋偵娭偡傞暥專儗價儏乕扴摉乯暯惉12擭搙岤惗楯摥徣堛椕媄弍昡壙憤崌尋媶帠嬈曬崘彂丂2002, pp1-12.
34丂姁扟桼壚丗娕岇婰榐偲僫儗僢僕儅僱僕儊儞僩乕姵幰僒乕價僗偺幙岦忋偵岦偗偨忣曬妶梡傪峫偊傞乕丆娕岇娗棟2002,12(7):524-6.
35丂姁扟桼壚丗堛椕偲娕岇偺尨揰丏帺庡偺摴丂2002,86崋:48-50.
36丂怷岥彯巎丆嵅摗愮巎丗HCV娭楢憗婜娞嵶朎娻偵懳偡傞愗彍+僀儞僞乕僼僃儘儞椕朄丏堛妛偺偁備傒丂2003, 204:283-4.
37丂壋娵徎悽丆姁扟桼壚丆嵅摗愮巎丗彫妛惗偵懳偡傞惗妶廗姷昦梊杊偺偨傔偺寬峃嫵堢偺偁傝曽偵娭偡傞暥專揑峫嶡丏
曐寬晈嶨帍 2003, 59(12):1172-7.
38 嵅摗愮巎丆崄寧婤巎丗擠晈偺撪壢恌椕-徚壔惈捵釃-丏Medical Practice 2003, 20:1517-20.
39 嵅摗愮巎丗寬峃偺奣擮丏憤崌曐寬堛椕榑乮垻晹弐巕丆嶳岥揙丂曇乯僰乕儀儖丒僸儘僇儚丂 搶嫗丂2003, pp18-pp24.
40 嵅摗愮巎丗媫惈娞墛丆枬惈娞墛丏椪彴尋廋幚慔儅僯儏傾儖乮撧椙怣梇丂曇乯撿峕摪丂搶嫗丂2003丆pp461-pp463.
41 嵅摗愮巎丗娞墛僂僀儖僗儅乕僇乕丗怴偟偄寣惔儅乕僇乕丏Medico 2003,34:125-7.
42 嵅摗愮巎丗C宆枬惈娞墛偵偍偗傞朢擜丒晜庮偲僋儕僆僌儘僽儕儞丏娞憻丂2004,45(3):133-138.
43 扟岥愮奊丆嵅摗愮巎丗娞丆抇丆鋁丆銪丆暊枌丏僫乕僗偺撪壢妛乮撧椙怣梇丒曇廤乯丆拞奜堛妛幮丆搶嫗丆2004, pp 269-342.
44 嵅摗愮巎丗徚壔婍幘姵丏椪彴堛妛奺榑乮搶梞椕朄妛峑嫤夛丒曇廤乯丆堛帟栻弌斉丆搶嫗丆2004, pp 21-56.
45 嵅摗愮巎丗僩儔儞僗傾儈僫乕僛丂摿廤丗専嵏抣傪撉傓丏撪壢 2004,93(6):1004.
46 嵅摗愮巎丗擕巁扙悈慺峺慺偲偦偺傾僀僜僓僀儉丂摿廤丗専嵏抣傪撉傓丏撪壢 2004,93(6):1005.
47 嵅摗愮巎丗徚壔婍昦妛丏椪彴岺妛億働僢僩僴儞僪僽僢僋乮廐梩棽娔廋丆愳嶈拤峴丆幣杮棽曇廤乯丆堛栻僕儍乕僫儖丆戝嶃丆2004, pp570-585.
48 嵅摗愮巎丗摟愅姵幰偵偍偗傞HCV姶愼崕暈偺偨傔偵偡傋偒偙偲乕僆僺僯僆儞2丏乽僆僺僯僆儞摿廤丂摟愅椕朄傪傔偖傞彅栤戣2004乿丆椪彴摟愅2004,20(7):965-968.
49 嵅摗愮巎丗媫惈丒枬惈娞墛偺栻暔帯椕丏儗僕僨儞僩僲乕僩丂2004,6(12):1563-1567.
50 怷岥彯巎丆嵅摗愮巎丗偙傟偐傜偺C宆娞墛帯椕-HCV-1b宆偵懳偡傞僆乕僟乕儊僀僪帯椕丏徚壔婍偺椪彴丂2005,8(2):204-208.
51丂媨愳敧暯丆嵅摗愮巎丗娞憻丒抇擷丏恖懱偺峔憿偲婡擻媦傃幘昦偺惉傝棫偪丏奺榑I乮崄愳桋梇懠曇乯丂撿峕摪丆搶嫗丂pp168-172, 2005.
52丂嵅摗愮巎丗婎杮堛妛棯岅帿揟乮撧椙怣梇曇廤乯丂拞奜堛妛幮丆搶嫗, 2005丏
53丂嵅摗愮巎丗娞墛僂僀儖僗姵幰偺帯椕丏摟愅堛椕偵偍偗傞姶愼徢梊杊丒帯椕儅僯儏傾儖乮廐梩棽曇廤乯擔杮儊僨傿僇儖僙儞僞乕丆搶嫗丂pp100-109, 2005.
54丂嵅摗愮巎丗娞婡擻儅乕僇乕丏摟愅姵幰偺儌僯僞儕儞僌乕偦偺慖戰偲峫偊曽丏椪彴摟愅 2005,21(7):829-836.
55丂媨愳敧暯丆嵅摗愮巎丗娞憻丒抇擷丏恖懱偺峔憿偲婡擻媦傃幘昦偺惉傝棫偪丏奺榑I乮崄愳桋梇懠曇乯丂撿峕摪丆搶嫗丂pp168-172, 2005.
56丂嵅摗愮巎丗婎杮堛妛棯岅帿揟乮撧椙怣梇曇廤乯丂拞奜堛妛幮丆搶嫗, 2005.
57丂扟岥愮奊丆嵅摗愮巎丗擠怭婜偵偍偗傞惗妶廗姷昦丏椪彴娕岇丂2005,31:2039-43.
58丂媨愳敧暯丆嵅摗愮巎丗惗妶廗姷昦偲旍枮丏 椪彴娕岇椪彴娕岇丂 2005,31:1876-83
59丂峳愳愮廐丆姁扟桼崄丆嵅摗愮巎丗岎懼惂嬑柋偲姤摦柆幘姵偲偺娭楢丏擔杮娕岇娗棟妛夛帍 2006,10(1):00-00.
60丂嵅摗愮巎丗儊僞儃儕僢僋僔儞僪儘乕儉偲帀朾娞丏椪彴塰梴 2006:106(6):751-756.
61丂嵅摗愮巎丗俫俠倁姶愼徢偺嵟怴偺帯椕丏摟愅姵幰偵偍偗傞擄帯惈姶愼徢乗嵟怴偺恌抐偲帯椕丏椪彴摟愅 2006,22(2):185-194.
62丂媣暷悏丆 嵶柤悈惗丆 嵅摗愮巎丗 僴乕僩僫乕僔儞僌 丂2006 (in press).
63丂嵅摗愮巎丆姁扟桼壚娔栿丗娕岇恌抐偵傕偲偯偔娕岇働傾婎弨丂戞侾姫乗戞3姫乮儅儕乕丒僕儍僼僃挊乯丏擔杮娕岇嫤夛弌斉夛丆搶嫗丆2006.
64丂峳愳愮廐丆姁扟桼崄丆嵅摗愮巎丗岎懼惂嬑柋偲姤摦柆幘姵偲偺娭楢丏擔杮娕岇娗棟妛夛帍 2006,10(1):30-36.
65丂嵅摗愮巎丗儊僞儃儕僢僋僔儞僪儘乕儉偲帀朾娞丏椪彴塰梴 2006:106(6):751-756.
66丂嵅摗愮巎丗HCV姶愼徢偺嵟怴偺帯椕丏摟愅姵幰偵偍偗傞擄帯惈姶愼徢乗嵟怴偺恌抐偲帯椕丏椪彴摟愅 2006,22(2):185-194.
67丂嵅摗愮巎丗AST (GOT), ALT (GPT). 嵟怴椪彴専嵏偺ABC丏擔杮堛巘夛嶨帍丂2006,135:S105-S108.
68丂嵅摗愮巎丗LD(H), LD(H) 傾僀僜僓僀儉丏嵟怴椪彴専嵏偺ABC丏擔杮堛巘夛嶨帍丂2006,135:S109-S112.
69丂媣暷悏丆嵶柤悈惗丆嵅摗愮巎丗嫊寣惈怱幘姵姵幰偺戅堾屻偺僗僩儗僗偵懳偡傞娕岇乗夁嫀5擭娫偺暥專揑峫嶡乗丏僴乕僩僫乕僔儞僌丂2006,19(109:60-64.
70丂嵅摗愮巎丆姁扟桼壚娔栿丗娕岇恌抐偵傕偲偯偔娕岇働傾婎弨丂戞侾姫乗戞3姫乮儅儕乕丒僕儍僼僃挊乯丏擔杮娕岇嫤夛弌斉夛丆搶嫗丆2006.
71丂憹揷岝巌丆嵅摗愮巎乮曇挊乯拞愳寬巌丆孏堜惓嶰丗棷妛惗偺偨傔偺擇娍帤岅偵婎偯偔婎慴堛妛弍岅妛廗帿揟丏杴恖幮丆搶嫗丆2006.
72丂嵅摗愮巎丗俠宆枬惈娞墛偵懳偡傞嵟怴偺栻暔椕朄丏儗僕僨儞僩僲乕僩丂2007,8(10):1411-1414.
73丂嵅摗愮巎丗枬惈娞墛丏傢偐傝傗偡偄撪壢妛乮戞3斉乯(曇廤丗堜懞桾)丂暥岝摪丂搶嫗丂2007.
74丂嵅摗愮巎丗娞憻丒抇擷丒鋁憻丏僫乕僗偺撪壢妛乮夵掕7斉乯(曇廤丗撧椙怣抝)丂拞奜堛妛幮丂搶嫗丂2007.
75丂嵅摗愮巎丗惗妶廗姷昦専恌丏擔杮寬峃堛妛夛嶨帍丂2007,16(2):6-9.5 嵅摗愮巎丗恖懱偺惗棟婡擻偲僨僩僢僋僗丏椪彴娕岇丂2007,33(10):1430-1435.
76丂嵅摗愮巎丗娞幘姵丆抇擷幘姵丆鋁憻幘姵丏傢偨偟偺偍堛幰偝傫丂庡晈偲惗妶幮丂搶嫗丂2007.
77丂抮揷惔巕丗崅楊幰偺懌偲僼僢僩働傾丏椪彴娕岇丂2007,33(1):49-55.



亂偦偺懠亃

1 Moriguchi H, Sato C: Treatment of SARS with human interferons. Lancet, 2003, 362:1159.
2 Moriguchi H, Sato C: Treatment of chronic hepatitis C in blacks and non-hispanic whites. New Engl J Med
2004,351:831-832.
3 嵅摗愮巎丗娞墛僂僀儖僗姶愼杊巭偵偮偄偰丏儚儞億僀儞僩傾僪僶僀僗丏Medical Practice 2004,21(8):1386.
4 嵅摗愮巎丗摿廤偵偁偨偭偰丏惗妶廗姷昦偺偡傋偰丏椪彴娕岇 2005,31:1865.



亂 妛夛 亃

1丂Kanoya Y. Kusaka K. Sato C.丗The effect bathing care using green tea grounds on dermatosis drug costs, ICN 22nd Quadrennial Congress; Copenhagen, Denmark; 10-15 June 2001. p.270.
2丂Kanoya Y. Tanaka R. Sato C.丗The relationship between the frequency of nurse乫s uniform exchange and the instruction by nursing directors in medium-scale hospitals in Japan, ICN 22nd Quadrennial Congress; Copenhagen, Denmark; 10-15 June 2001. p.305.
3 姁扟桼壚丆徖揷旤岾丆摗尨懽巕丆擔壓榓戙丆嵅摗愮巎丗羼釋傪桳偡傞姵幰傊偺朘栤娕岇働傾偺僋儕僥傿僇儖僷僗朄摫擖偵傛傞岠壥?羼釋偺帯桙偲娕岇晈偺堄幆偵徟揰傪偁偰偰乕丏戞俁夞擔杮羼釋妛夛妛弍廤夛丂嫗搒丆10寧21-22擔.
4 姁扟桼壚丆擔壓榓戙丆嵅摗愮巎丗娕岇偺幙傪曐徹偟丆憗婜戅堾傪傔偞偟偨僋儕僥傿僇儖僷僗朄偺奐敪丏 戞21夞擔杮娕岇壢妛妛夛妛弍廤夛丂恄屗丆 12寧侾-2擔.
5 擔壓榓戙丆姁扟桼壚丆嵅摗愮巎丆媨杮恀枻丗娕岇戝妛惗偲堦斒彈巕戝惗偲偺惛恄忈奞幰偵懳偡傞僀儊乕僕偺斾妑丏 戞21夞擔杮娕岇壢妛妛夛妛弍廤夛丂恄屗丆 12寧侾-2擔.
6 watanabe H, Kanoya Y, Kusaka K, Takada E and Ishikawa I. Effect of a novel masticatory product on oral and immunological functions. Oral Diseases and Systemic Health, 1st International Congress on Mastication and Health, 2002, 15th September
7 墊杮怣岾丆搉曈庣丆嵅摗愮巎丗HCV replicon system 偵傛傞HCV 堚揱巕曄堎偲峈僂僀儖僗帯椕岠壥偺夝愅丏僔儞億乽僂僀儖僗娞墛偵懳偡傞愴棯-昦懺夝柧偐傜帯椕偺岦忋傊乿戞38夞擔杮娞憻妛夛憤夛丆戝嶃丆2002, 6/13
8 怷岥彯巎丆嵅摗愮巎丗憗婜HCV娭楢娞嵶朎娻姵幰偵懳偡傞嵟揔帯椕愴棯暘愅儌僨儖丏僔儞億乽変偑崙偺幚忬偵偁偭偨娞娻帯椕傪媮傔偰丗娞堏怉偲嬊強椕朄乿戞6夞擔杮娞憻妛夛戝夛丆墶昹丆2002, 10/24
9 墊杮怣岾丆搉曈庣丆嵅摗愮巎丗寬恌僙儞僞乕偵偍偗傞堦斒専恌傊偺娞墛僂僀儖僗専嵏偺摫擖丏僔儞億乽21悽婭偺娞娻専恌-娞墛専恌偲偟偰偺庢傝慻傒乿戞6夞擔杮娞憻妛夛戝夛丆墶昹丆2002, 10/25
10 姁扟桼壚丆擔壓榓戙丆拞嶳塰弮丆嵅摗愮巎丗惛恄忈奞幰偺帺変懺搙偲僗僩儗僗僐乕僺儞僌偵娭偡傞尋媶. 戞28夞擔杮娕岇尋媶妛夛丆2002, 8/7
11 擔壓榓戙丆姁扟桼壚丆嵅摗愮巎丗怑柋偺婜懸搙偑娕岇怑枮懌搙傊梌偊傞塭嬁. 戞28夞擔杮娕岇尋媶妛夛妛弍廤夛丆2002, 8/7
12 姁扟桼壚丆擔壓榓戙丆嵅摗愮巎丗羼釋偵懳偡傞億儕僼僃僲乕儖揧壛惗棟怘墫悈偵傛傞愻忩偺岠壥偵娭偡傞尋媶. 戞係夞擔杮羼釋妛夛丆2002, 8/31
13 姁扟桼壚丆擔壓榓戙丆嵅摗愮巎丗懱埑暘嶶怮嬶偺岠壥斾妑偵娭偡傞尋媶?愙怗埑傊偺塭嬁偐傜乕. 戞係夞擔杮羼釋妛夛丆2002, 8/31
14 Moriguchi H, Chung RT, Kobayashi M, Sato C: Tumor ablation plus interferon therapy for HCV-related early hepatocellular carcinoma: a meta-analysis of randomized controlled trial. The 54th AASLD Annual Meeting, Boston, 2003, October 24-28.
15丂Kanoya Y, Sawayama Y, Sato C: A study on the influence of nursing manager's leadership on nurses' job satisfaction and hospital management. International Congress on Nursing, Geneva, 2003, 27th June.
16丂楅栘塸巕丆崄寧婤巎丆姁扟桼壚丗Rathus assertiveness schedule擔杮岅斉奐敪偵娭偡傞尋媶丆擔杮惛恄曐寬娕岇妛夛丆搶嫗丆俇寧丆2003.
17丂姁扟桼壚丆驸渑丆擔壓榓戙丆嵅摗愮巎丗娗棟怑偺僄僑僌儔儉僷僞乕儞偲娕岇怑怑柋枮懌搙丆擔杮娕岇尋媶妛夛丆戝嶃丆俈寧丆2003.
18丂搉曈媣丆姁扟桼壚丆擔壓榓戙丆崅揷奊棟巕丆嵅摗愮巎丆峳愳恀堦丆愇愳楏丆壛摗廏庽丆崅栰惓怣丗岥峯婡擻偍傛傃婰柫椡偵懳偡傞崅楊幰梡欚殣怘昳偺岠壥偵娭偡傞尋媶丆戞14夞擔杮欚殣妛夛丆摽搰丆俋寧丆2003.
19丂壋娵徎悽丆姁扟桼壚丆搉曈媣丆擔壓榓戙丆嵅摗愮巎丗僌儈欚殣偑彫妛惗偺怱棟忬懺偍傛傃岥峯婡擻偵梌偊傞塭嬁偵娭偡傞尋媶丆戞14夞擔杮欚殣妛夛丆摽搰丆俋寧丆2003.
20丂Moriguchi H, Sato C: Statistical analysis of combined substitutions in NS5A 2209-2218 of hepatitis C virus 1b infection and standard or pegylated interferon plus ribavirin therapy response. The 105th Digestive Disease Week Annual Meeting, New Orleans, LA, 2004, May 15-20.
21丂Moriguchi H, Sato C: A predictive method for HCV-related hepatocellular carcinoma by using clinical genomics-meta-analysis of individual patient data. the 2004 Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 2004, June 5-8.
22丂Kanoya Y, Sawayama Y, Sato C: Consideration of the statement for nursing activity in the law for nurses in Japan. International Congress on Nursing, Amsterdum, 2004, June 27.
23丂Kanoya Y, Sawayama Y, Sato C: The critical pathway as a screening of long term hospitalization. International Congress on Nursing, Amsterdum, 2004, June 27.
24丂Kanoya Y, Sawayama Y, Sato C: The effect of washing care with polyphenol in patients with diaper. International Congress on Nursing, Amsterdum, 2004, June 27.
25丂Kanoya Y, Sawayama Y, Sato C: The effects of critical pathways on patients' satisfaction and longitudinal 丂丂
丂nurses' satisfaction. International Congress on Nursing, Amsterdum, 2004, June 27.
26丂Kusaka K, Kanoya Y, Katsuki T, Sato C: Standardization of treatment and nursing of the critical path method introduction and its effect on an early discharge from hospital in an acute phase psychiatry unit. International Congress on Nursing, Amsterdum, 2004, June 27.
27丂Suzuki E, Kanoya Y, Katsuki T, Sato C: Verification of the reliability and validity of a Japanese version of the Rathus assertiveness schedule.. 崙嵺娕岇壢妛妛夛, Kohriyama, 2004, August 29.
28丂Kanoya Y, Katsuki T, Kusaka K, Suzuki E, Sato C: Introduction of a nurses' critical pathway and satisfaction. 崙嵺娕岇壢妛妛夛, Kohriyama, 2004, August 29.
29丂巺曱堦榊丆楅栘塸巕丆姁扟桼壚丆嵅摗愮巎丗儕傾儕僥傿僔儑僢僋偵娭偡傞尋媶乮偦偺1乯-暥專専摙偐傜-丏戞30夞擔杮娕岇尋媶妛夛妛弍廤夛丆偍偍傒傗丆2004擭7寧29擔.
30丂楅栘塸巕丆巺曱堦榊丆姁扟桼壚丆嵅摗愮巎丗儕傾儕僥傿僔儑僢僋偵娭偡傞尋媶乮偦偺2乯-怴懖娕岇巘偺娭楢梫場暘愅-丏戞30夞擔杮娕岇尋媶妛夛妛弍廤夛丆偍偍傒傗丆2004擭7寧29擔.
31丂暯堜偝傛巕丆夑戲栱婱丆忋揷抭巕丆幱奀灘丆楅栘塸巕丆曅壀桼旤巕丆憪姞弤巕丆嵅摗愮巎丗椪彴偵偍偗傞娕岇怑偺 The Nursing Activity Scale 偺怣棅惈丒懨摉惈偺専摙乚愱栧怑帺棫惈偺應掕乚丏戞8夞擔杮娕岇娗棟妛夛擭師戝夛丆塅搒媨丆2004擭8寧20擔乣21擔丏
32丂Kanoya Y, Sato C: A study on the methods of screening to detect patients' needs for early discharge. 23rrd Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
33丂Katsuki T, Kanoya Y, Sato C: Bibliographical consideration of psychiatric effects of terrorism-related media coverage on general population. 23rrd Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
34丂Kanoya Y, Ueda M, Inoue N, Ikeda S, Sato C: The present situation of cooperative sections with community in acute-care hospitals and their influence on the length of stay. 23rrd Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
35丂Kanoya Y, Inoue N, Ueda M, Ikeda S, Yoshiya F, Sato C: Education system for safety management in hospitals and their nurses' recognition on safety. 23rrd Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
36丂Kanoya Y, Izuha K, Sato C: Hospitals' instructions on the word-type used by nurses and their relations with patients' satisfaction. 23rrd Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
37丂Kusaka K, Kanoya Y, Katsuki T, Kusaka C, Yanagawa H, Sato C: Study on the relevance among mentally handicapped persons' QOL, ego attitudes and stress copings to them. 23rrd Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
38丂Kusaka K, Kanoya Y, Katsuki T, Kusaka C, Yanagawa H, Sato C: Study on factors related to early discharge and support in public in chronic mentally handicapped people. 23rrd Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
39丂Suzuki E, Kanoya Y, Sato C: Workplace Environment, Assertiveness and Burnout among Novice Nurses in University Hospitals. 23rrd Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
40 Moriguchi H, Sato C: The 99th annual meeting of American Association for Study of Liver Diseases. San Francisco, 2005.
41 Kanoya Y, Ueda M, Inoue N, Ikeda S, Sato C: The present situation of cooperative sections with community in acute-care hospitals and their influence on the length of stay.丂23rrd  Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
42丂Kanoya Y, Inoue N, Ueda M, Ikeda S, Yoshiya F, Sato C: Education system for safety management in hospitals and their nurses' recognition on safety. 23rrd  Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
43丂Kusaka K, Kanoya Y, Katsuki T, Kusaka C, Yanagawa H, Sato C: Study on the relevance among mentally handicapped persons' QOL, ego attitudes and stress copings to them. 23rrd  Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
44丂Kusaka K, Kanoya Y, Katsuki T, Kusaka C, Yanagawa H, Sato C: Study on factors related to early discharge and support in public in chronic mentally handicapped people. 23rrd  Quadrennial Congress of the International Council of Nursing, Taipei, May 21-27, 2005.
45丂愇揷掑戙丆朷寧岲巕丆娭崻棿巕丆楅栘塸巕丆懞徏柧旤丆塝揷徠旤丆彫挿扟岲峕丆峟扟愮戙巕丆嵅摗愮巎丗羼晈傊偺欚殣巜摫偺嶻屻1儢寧偵偍偗傞桳岠惈丏擔杮娕岇妛夛乮曣惈娕岇乯丆栘峏捗丆7寧14擔丆2005.
46丂楅栘塸巕丆姁扟桼壚丆嵅摗徃巕丆嵅摗愮巎丗戝妛昦堾偵嬑柋偡傞怴懖娕岇巘偺僶乕儞傾僂僩敪徢偵娭偡傞廲抐尋媶丏擔杮娕岇尋媶妛夛憤夛丆嶥杫丆7寧21擔-22擔丆2005丏
47丂Moriguchi H, Uemura T, Sato C, Chung RT: Tumor ablation plus interferon therapy can reduce the risk of death for patients with hepatitis B virus or hepatitis C virus-related respectable hepatocellular carcinoma-a meta-analysis of randomized controlled trial. The 55th AASLD annual meeting, Boston, October 27-31, 2006.
48丂Katsuki T, Suzuki E, Sato C: Assessment of patients with dementia and functional disorders in nursing home -Effective use of the Gordon's functional healthy pattern-. Ankara, 2006.
49丂楅栘塸巕丆屷嵢抦旤丆姁扟桼壚丆崄寧婤巎丆嵅摗愮巎丗戝妛昦堾偵嬑柋偡傞怴懖娕岇巘偺憗婜戅怑偺塭嬁梫場偵娭偡傞廲抐尋媶丏戞32夞擔杮娕岇尋媶妛夛妛弍廤夛丆暿晎丆8寧24擔-25擔丆2006.丂
50丂Morikagi, Y., Kanoya, Y., Ohtake, M., Tashiro, H., Sato, C: Evaluation of the validity of the screening tool to support early discharge in acute hospitals. ICN Conference 2007,Yokohama, Japan,27 May-1June 2007.
51丂Kanoya Y, Suzuki I, Ohtake M, Saito A, Kobayashi A, Funada T, Shimizu H, Sato C丗A study on nursing students丂of recognition of rural medicine in Japan. 5Th International Congress, Albury, March 2007
52丂Kusaka K, Yanagawa H, Katuki T, Yabe Y, Nagasaka S, Kanoya Y, Sato C丗A study on the self-understanding of nurses and care for patients, ICN Conference and CNR, Yokohama, May-June 2007
53丂Katsuki T, Kanoya Y, Suzuki E, Kusaka K, Sato C丗Bibliographical consideration of mental effects by terrorism-related media coverage, ICN Conference and CNR, Yokohama, May-June 2007丂
54丂Kanoya Y, Kusaka K ,Ohtake M, Saito A, Suzuki I, Kobayashi A, Sato C丗A study on the effect of a critical path for pressure ulcers, Care Pathway 2007, London, June 2007
55丂Kobashi H, Fujioka S, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Takaki A, Iwasaki Y, Sakaguchi K, Shiratori Y, Ishikawa H, Omata M. Emergence od hepatitis B virus gene mutation related to Entecavil-resistance in chronic hepatitis B patients participated in the phase 2 clinical studies of Entecavir in Japan. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, November 2-6, 2007.
56丂怷尞桽巕丆戝抾傑傝巕丆姁扟桼壚丆釼摗柧巕丆楅栘堢巕丆彫椦弤巕丆揷戙媣抝丆嶚尨棽巕丗戅堾巟墖愱栧晹彁偐傜戅堾巟墖傪庴偗偨崅楊姵幰偺椕梴惗妶忬嫷丏戅堾1儢寧屻偺捛愓寢壥偐傜丏戞11夞擔杮嵼戭働傾妛夛妛弍廤夛丆暯惉19擭3寧4擔丆嶉嬍丏
57丂敀栘桼壴丆媨撪惔巕丆嵅媣娫梉旤巕丆嵅摗愮巎丗儓僈偺崢捝娚榓岠壥丏戞23夞擔杮寬峃壢妛妛夛妛弍戝夛丆暯惉19擭11寧11擔丆搶嫗
58丂嵅媣娫梉旤巕丆桭摗桾旤丆媨撪惔巕丆嵅摗愮巎丗僠儑僐儗乕僩旀楯梷惂岠壥丏戞17夞擔杮寬峃堛妛夛憤夛丆暯惉19擭11寧10擔丆搶嫗
59丂嵶柤悈惗丆姁扟桼壚丆朷寧岲巕丆愇岝晣旤巕丆媣暷悏丆妏娫梉旤巕丆嵅摗愮巎丗怱憻僇僥乕僥儖専嵏傪庴偗傞姵幰偺晄埨傊偺専嵏愢柧儕儔僋僙乕僔儑儞僾儘僌儔儉偺岠壥丏戞27夞擔杮娕岇壢妛妛夛妛弍廤夛丆暯惉19擭12寧8擔丆搶嫗
60丂楅栘塸巕丆嵵摗怺愥丆恀栘抭丆屷嵢抦旤丆崄寧婤丆嵅摗愮巎丗怴懖娕岇巘偺憗婜棧怑偲僶乕儞傾僂僩偲傾僒乕僥傿僽僱僗丏戞27夞擔杮娕岇壢妛妛夛妛弍廤夛丆暯惉19擭12寧8擔丆搶嫗6丂戝抾傑傝巕丆揷戙媣抝丆崅嫶揘巕丆釼摗柧巕丆怷尞桽巕丆楅栘堢巕丆彫椦弤巕丆姁扟桼壚丗媫惈婜昦堾偲朘栤娕岇僗僥乕僔儑儞偲偺楢実偵偍偗傞壽戣丆戞11夞擔杮嵼戭働傾妛夛妛弍廤夛丆2007
61丂戝抾傑傝巕,戝扟曕,廆宍徑,釼摗柧巕,楅栘堢巕,彫椦弤巕,姁扟桼壚丆戝娧媊恖丆楅栘 敊丆嵅摗 庒丗嶳宍導帣摱偺懱奿丒懱椡丒惗妶廗姷偺悇堏乗暯惉12乣17擭偺怴懱椡僥僗僩偺寢壥傛傝乗丆戞33夞嶳宍導岞廜塹惗妛夛丆2007
62丂戝抾傑傝巕丆釼摗柧巕丆楅栘堢巕丆姁扟桼壚丆彫椦弤巕丗乽偨偽偙乿懳嶔偵娭偡傞抧堟娕岇妛墘廗偺岠壥丆戞33夞擔杮娕岇尋媶妛夛妛弍廤夛丆2007

亂 尋媶妶摦 亃

僔儞億僕僂儉

1丂嵅摗愮巎丗娞墛僂僀儖僗偺堾撪姶愼傪杘柵偡傞偨傔偵丏戞46夞擔杮摟愅堛妛夛僔儞億僕僂儉8乽堾撪姶愼杘柵傪栚巜偟偨21悽婭偺摟愅堛椕徢乿戝嶃丂6寧22-24擔.
2丂嵅摗愮巎丗戞10夞DDW-Japan 擔杮娞憻妛夛丒擔杮徚壔婍廤抍専恌妛夛崌摨僔儞億僕僂儉9乽娞娻杘柵傪栚巜偟偨専恌乿巌夛丏墶昹丂10寧25擔.
3丂嵅摗愮巎丗惗妶廗姷昦専恌丏乮僔儞億僕僂儉乽専恌偺栶妱乿丆戞11夞寬峃堛妛夛丆搶嫗丆11寧11擔丆2006.


尋媶彆惉嬥丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂丂

壢妛尋媶旓曗彆嬥丂婎斦C丂娕岇巘偺僶乕儞傾僂僩偲傾僒乕僥傿僽僱僗側帺屓昞尰偵娭偡傞尋媶乮戙昞丟楅栘塸巕乯乮暯惉15擭搙 暯惉17擭搙乯
壢妛尋媶旓曗彆嬥丂婎斦C丂娕岇巘惗奤嫵堢偺擔拞斾妑乮戙昞丟暯堜偝傛巕乯乮暯惉16擭搙 暯惉18擭搙乯
壢妛尋媶旓曗彆嬥丂婎斦C丂擣抦峴摦椕朄傪妶梡偟偨羼晈傊偺挿婜欚殣巜摫偵娭偡傞柍嶌堊壔斾妑尋媶乮戙昞丟愇揷掑戙乯乮暯惉17擭搙 暯惉19擭搙乯
壢妛尋媶旓曗彆嬥丂婎斦C丂羼釋偵桳岠側愻忩曽朄丆塰梴偵娭偡傞尋媶乮戙昞丟姁扟桼壚乯乮暯惉17擭搙 暯惉20擭搙乯
壢妛尋媶旓曗彆嬥丂庒庤B丂娕岇巘偺岎懼惂嬑柋偑寚嬑傗堛椕儈僗偵梌偊傞塭嬁偵娭偡傞尋媶乮戙昞丟峳愳愮廐乯乮暯惉18擭搙 暯惉19擭搙乯
岞塿怣戸 嶳楬傆傒巕愱栧娕岇嫵堢尋媶彆惉婎嬥 尋媶彆惉丂CCU偵擖堾偟偨嫊寣惈怱幘姵姵幰傊偺儕儔僋僛乕僔儑儞僾儘僌儔儉偺岠壥偺専摙乮媣暷丂悏乯乮暯惉17擭搙乯
岤惗壢妛尋媶乮戙昞丟廐梩棽乯乮暯惉18擭搙乯


幮夛妶摦
1丂嵅摗愮巎丗擔杮撪壢妛夛丂擣掕撪壢堛丆巜摫堛
2丂嵅摗愮巎丗擔杮娞憻妛夛丂愱栧堛丆巜摫堛丆昡媍堳
3丂嵅摗愮巎丗擔杮徚壔婍昦妛夛丂愱栧堛丆巜摫堛丆妛夛昡媍堳
4丂嵅摗愮巎丗嶻嬈堛